Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model
Open Access
- 13 January 2022
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 530, 8-15
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science and Technology, Taiwan (106-2314-B-040-026-MY2, MOST 108-2314-B-040-014-MY3)
- Chung Shan Medical University Hospital (CSH-2019-C-031)
This publication has 24 references indexed in Scilit:
- IL-10 Promotes Tumor Aggressiveness via Upregulation of CIP2A Transcription in Lung AdenocarcinomaClinical Cancer Research, 2013
- Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicityCancer Chemotherapy and Pharmacology, 2011
- VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating SurvivinMolecular and Cellular Biochemistry, 2011
- A Polymorphic −844T/C in FasL Promoter Predicts Survival and Relapse in Non–Small Cell Lung CancerClinical Cancer Research, 2011
- A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cellsBiochemical and Biophysical Research Communications, 2010
- Histone deacetylases and cancerOncogene, 2007
- Cleavage and degradation of Claspin during apoptosis by caspases and the proteasomeCell Death & Differentiation, 2007
- The case for survivin as a regulator of microtubule dynamics and cell-death decisionsCurrent Opinion in Cell Biology, 2006
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984
- Bladder cancer and N-methyl-N-nitrosourea II. Sub-cellular changes associated with a single noncarcinogenic dose of MNUChemico-Biological Interactions, 1973